In this study, blockade with anti-MCP1 and anti-IL-6 antibodies alone or in combination under hypoxia increased NK cell killing activity against HCC through the upregulation of NKG2D and NKp44, which are NK activation receptors (Figure 6). This evidence concerns the gene CCL2 and hepatocellular carcinoma.